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ABSTRACT 
Objective: The motivation behind the current examination was to build the solvency and dissolution rate of an antihypertensive drug telmisartan 
by the planning of nanosuspension by precipitation method at the research facility scale. We researched the nanoparticle manufacture of 
telmisartan employing a 33 factorial experimental configuration considering the impacts of nanosuspension on the physical, morphological, and 
dissolution properties of telmisartan.  
Methods: To get ready, nanosuspension particles of an ineffectively dissolvable drug are moreover of a drug solution to the anti-solvent leads to 
abrupt supersaturation and precipitation the making of nanoparticles. The nanosuspension particles of a poorly soluble drug loaded with urea and 
surfactants (sodium lauryl sulfate (SLS), poloxamer 188, Tween 80) have been prepared by a precipitation method. The nanosuspension particles 
were characterized for particle size, zeta potential, Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), in 
vitro drug release, and release kinetics.  
Results: The readily optimized batch nanosuspension particles evaluated and exhibited the particle size (750 nm), zeta potential (-24.33 mV), 
differential scanning calorimetry (DSC) drug exhibited a change in crystalline form to amorphous, in vitro dissolution (F12 was higher 95% within 5 
min) and drug release kinetics. The formulation parameter of surfactant concentration is optimized.  
Conclusion: The formulation of the nanosuspension approach has been shown to substantial improvement in the dissolution rate, thereby 
enhancing the oral bioavailability with the future development of this technology.  
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INTRODUCTION 
The most convenient and universally adopted route for the drug 
delivery system is an oral route because it is highly flexible for 
designing the dosage form as contrasted with other drug delivery 
systems [1]. The term nanotechnology, inferred from the Greek word ‘nano’, meaning ‘dwarf’, applies to the engineering principles, natural 
philosophy and material science, electronics, and manufacturing at a 
molecular or submicron level. The nanoscale materials might be a 
gimmick or a system or these could be supramolecular structures, 
complexes, or composites. Albert Franks defined, during the former 
promoter of nanotechnology ‘in the area of scientific discipline and 
technology where standard particle dimensions are from 0.1 nm to 
1000 nm in range. In the mainstream biomedical applications, 
significant rises are made by nanotechnology, as easily as in the fields 
of drug release, gene therapy, imagery, and novel drug discovery 
systems [2, 3]. The overall rise of nanoscale science and engineering 
set apart by the declaration of the national nanotechnology initiative 
(NNI) in January 2000. Current investigation on Biosystems at the 
nanoscale has made one of the most unique science and technology 
domains at the union of physical sciences, atomic engineering, natural 
science, biotechnology, and drug. Nanotechnology is portrayed as a 
field that puts on the nanoscale benchmarks and strategies to 
comprehend and modify bio-systems (living or non-living) and which 
uses natural guidelines and constituents to make new contraptions 
and systems composed from the nanoscale [4]. For expanding drug 
markets, NDDS represents an intended tool for the pharmaceutical 
industries. The engineering development is assisting and enhancing 
pharmaceuticals such as expanding product age or can enhance their 
performance, either by increasing therapeutic effectiveness or 
improving safety and patient compliance [5]. In recent years novel 
drug delivery systems (NDDS) like nanosuspensions draw heavy 
attention in the search for improving the bioavailability of poorly 
soluble drugs [6, 7]. The colloidal submicron dispersal of medication 
particles is nanosuspension. A pharmaceutical nanosuspension 
characterized as finely colloid biphasic, scattered, strong medication 
particles in an aqueous vehicle, size underneath 1 µm, with no matrix 
solid, dissolved by surfactants and polymers, arranged by reasonable 
strategies for drug delivery applications, through different courses of 
administration like oral, skin, parenteral, ophthalmic and pulmonic 
routes. A nanosuspension does not handle poor dissolvability and 
bioavailability yet, furthermore, modifies the pharmacokinetics of the 
drug, and that enlarges drug safety and efficacy. In nanosuspension 
innovation, the drug kept up with the required crystalline state with 
decreased molecule size, prompting an expanded dissolution rate and 
in this way, enhanced bioavailability [8]. Nanosuspension 
characterized as “in a watery vehicle very fine particles are outspread, 
stabilized by surface-active agent, for together oral and topical use and 
parenteral and pulmonary administration, causing a small particle 
size, dissolution rate increases and thus improved bioavailability”. The diameter of the suspended nanoparticles is less than 1 μm in size (i.e. 
0.1 nm-1000 nm) [9-11]. Similarly, for class II drugs, which are poorly 
aqueous soluble and also in organic media, the problem is more 
complex [2]. The compounds that are polar-insoluble (oil soluble), 
favored for getting ready nanosuspensions with more log P-value. 
Consequently, the rate of the overflowing of the therapeutic action 
compound increases, and the maximum plasma drug level is passed 
quickly e. g., oral or parenteral administration of the nanosuspensions. 
The orally active non-peptide angiotensin II antagonist is identified as 
telmisartan, which takes a shot at the AT1 receptor subtype. Among 
commercially available angiotensin receptor blockers (ARBS), it 
delivers the highest affinity for the AT1 receptor and has negligible 
affinity for the AT2 receptor [12]. The diligence of the nanosuspension 
systems in the treatment of high blood pressure remains to go wider, 
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however; mechanization is not sufficient for many new drugs those 
are very less soluble, which prompted the development of nanoscale 
systems. By decreasing the particle size from a micrometer to a 
nanometer scale, in that location is a substantial increase in 
dissolution rate due to increasing the surface area [13, 14]. Antisolvent 
precipitation procedure is a promising strategy to manufacture 
ultrafine drug particles, which depends on the difference in super 
saturation brought by blending the solution and the antisolvent [15, 
16]. In this current study, nanoprecipitation precipitation strategy is 
utilized where a drug solution in a water-miscible organic solvent 
blended with an aqueous solution comprising a surfactant. After 
blending, the supersaturated solution prompts nucleation and 
development of drug particles, which might be stabilized by 
surfactants. The fundamental target of the current investigation is to 
perform the preparation and evaluation of nanosuspensions of anti-
hypertensive drug Telmisartan by utilizing appropriate polymers to 
enhance its bioavailability. A 33 factorial design was employed to 
explore the joined impact of 3 formulation variables [17]. 
MATERIALS AND METHODS 
Materials 
The gift sample telmisartan was acquired from Matrix Laboratory 
Limited, Hyderabad, India. Poloxamer 188 and Tween 80 was 
procured from Torrent Pharmaceuticals Ltd, Ahmadabad and Shreeji 
Pharma International, Vadodara, India. Urea and SLS bought from 
Rankem Pvt Ltd, India. From the authorized dealer, all other 
chemicals procured are analytical grade [3, 5, 18]. 
Methodology 
Ultraviolet spectroscopy 
A stock solution of telmisartan, 10 µg/ml in a buffer of 0.1 N HCL 
prepared and scanned in UV-Vis spectroscopy between 200-400 nm 
and the scanned drug  max traced out [19-21]. 
Preparation of calibration curve 
The 20 mg of pure drug solubilized in 20 ml of methanol and its 
concentration becomes 1000 µg/ml. From the above solution, 10 ml 
withdrawn and dissolved in 100 ml of 0.1N HCl to give 
concentration 100 µg/ml and is named as a stock solution. From the 
of prepared, 100 µg/ml stock solution, sequential dilutions set up by 
withdrawing 0.5, 1, 1.5, 2, 2.5 and 3 ml, which were a build-up to a 
volume of 10 ml each, in individual volumetric flasks to get the 
separate concentrations of 5, 10, 15, 20, 25 and 30 µg/ml and named 
appropriately. The calibration curve of telmisartan then constructed 
by scanning the respective serial dilutions of the drug solution (5, 
10, 15, 20, 25, 30 µg/ml) using UV-Vis spectroscopy at the 
wavelength of maximum absorption ( max) [19-22]. 
Formulation design and preparation of telmisartan 
nanosuspension 
While formulating a steady suspension with the smallest particle size, a 
top nucleation rate but a low growth rate is essential. Both rates are 
reliant on temperature: the ideal temperature for nucleation may lie 
beneath that for crystal development, which grants temperature 
optimization. Nanosuspensions set up by the solvent evaporation 
procedure and by precipitation method, the nanosuspension particles of 
a poorly soluble drug have been prepared.  
In this process, telmisartan solubilized in methanol at room 
temperature and it poured into an anti-solvent (water) comprising 
urea and separate quantity of poloxamer 188, Tween 80, SLS, or in 
combination in various formulations continued at room temperature 
and afterward stirred on a magnetic stirrer (Remi, India.). The same 
quantity of telmisartan and urea was mixed and rapid addition of this 
solution through a needle situated with the syringe, directly into 
stabilizer/surfactant solution holding anti-solvent leads to sudden 
supersaturation of the drug. Stabilizers intended to wet the outer 
surfaces of the particles and prevent Ostwald ripening and 
agglomeration to increase the stability of the preparation by providing 
a thick barrier on the outer surfaces of the particles and exhibit a 
uniform disperse stage. By evaporating organic solvents in slow 
magnetic stirring conditions at room temperature for 1 h the initiation 
of ultrafine solid crystalline or amorphous particles developed and the 
crystal grows in two stages one is nuclei formation and another is 
crystal growth [23, 24]. Afterward, prepared nanosuspension 
sonicated for 1 h for getting uniform size particles [25, 26]. 
 
Table 1: Formulae of telmisartan nanosuspension 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Telmisartan (mg) 40 40 40 40 40 40 40 40 40 40 40 40 
Urea (mg) 40 40 40 40 40 40 40 40 40 40 40 40 
SLS (mg) 3 5 10 - - - - - - - - - 
Poloxamer 188 (mg) - - - - - - 3 4 5 5 5 5 
Tween 80 (%) - - - 0.1 0.2 0.3 - - - 0.1 0.2 0.3 
Water (ml) 30 30 30 30 30 30 30 30 30 30 30 30 
Note: (-) the particular excipient not utilized in the formulation. 
 
Table 2: 33 experimental design layouts 
Coded factors and units Coded levels 
Low level Middle level High level 
 -1 0 1 
X1: SLS (mg) 3 5 10 
X2: Poloxamer 188 (mg) 3 4 5 
X3: Tween 80 (%) 0.1 0.2 0.3 
 
Experimental design 
The 33 factorial design is one of the procedures to examine the impact 
of various factors on the quality determinant parameters of any 
formulation. Given the guideline of a plan of examinations, this 
structure is utilized to explore the impact of three autonomous factors. 
Experimental design utilized in the present inspection for the 
optimization of excipients concentration, such as the concentration of 
SLS, poloxamer 188, and Tween 80 specified as factors X1, X2, and X3 
learned at 3 levels each. Table 3 summarizes a record of the twelve-
formulation examined, their factor combinations, and the coded levels 
to the experimental units utilized during the study. Formulae for all 
the experimental batches given in table 1 [5, 17, 27, 28]. 
Drug polymer interaction study 
The powdered drug telmisartan and physical mixture of telmisartan 
and other excipients (best formulation) compatibility property 
originated by FTIR by utilizing Bruker Optics [29]. The compatibility 
study and variations in the chemical composition of the medicament 
after blending with excipients inspected by FTIR (Tensor 27, Bruker 
Optics, Germany) in the 4000-400 cm-1frequency range [30].  
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Particle size analysis 
In a microtrac blue wave-particle size analyzer, the particle size of 
the optimized formulation analyzed. The samples diluted with de-
ionized water to get a suitable concentration for measurement [3, 
18]. The particle size distribution achieved results applied to 
support the formation of nanosized particles [9, 23]. 
Zeta potential measurement 
It is a term identified with the stability of samples of atoms and 
particles that are little enough; superior zeta potential will give 
stability i.e. it opposes accumulation. The zeta potential of the 
suspended particles of optimized formulation wares measured in 
Malvern zetasizer (Zetasizer 3000 HS, Malvern instrument, UK). A 
laser is available in the zetasizer, which employed to give light 
energy to illuminate the particles within the sample. When the 
splitting of light makes an incident and a reference beam, the zeta 
potential is assessed. Through the middle of the sample cell when 
the incident laser beam reaches, the scattered light at a 130 ° angle is 
detected. Zetasizer nano software generates a frequency spectrum 
from which the electrophoretic mobility thus, the zeta potential 
forecasted [21, 28, 31, 32]. 
Differential scanning calorimetry 
Pure drug and drug-loaded optimized formulation nanosuspensions 
containing drug telmisartan DSC analysis carried out using DSC Q20 (TA 
Instruments, USA) to examine any potential drug-polymer interaction. 
The sample drug and nanosuspension weighed 5 mg and 5.2 mg under a 
nitrogen flow of 25 ml min-1 heated at a scanning rate of 10 °C min-1 the 
analysis performed from temperature range 25 °C to 300 °C. Utilizing TA 
instruments (version: 4.5A) universal analysis 2000 software, thermal 
data analysis of DSC thermograms directed [33-35]. 
Scanning electron microscopy 
The surface morphology specimen originated with the assistance of 
a SEM, Model JSM 84 0A, JEOI, Japan. In a vacuum desiccator, the 
samples are becoming completely dry by using double-sided 
adhesive tape, before climbing up on brass specimen studies. The 
gold-palladium alloy of 12 nm knee coated on the sample sputter 
coating unit (Model E5100 Polaron U. K) using argon at an ambient 
of 8-10 plus plasma voltage around 20 mA. The sputtering was 
accomplished for about 5 min to get uniform covering on the sample 
to empower outstanding quality SEM pictures. The SEM was 
functioning at a less accelerating voltage of around 20 kV with a 
burden current around 80 mA [27, 36]. 
Dissolution study 
The in vitro drug release studies performed in USP dissolution 
apparatus Type II (paddle type) (Labindia DS-800) at 50 rpm. The 
dissolution test operated out in 0.1 N HCl 900 ml dissolution 
medium and temperature at 37.0±0.5 °C. 5 ml of the test sample 
pulled back from the dissolution basket periodically and replaced 
with an equivalent volume of fresh 0.1 N HCl after every sampling. 
The 5 ml 0.1 N HCl withdrawn samples suitably diluted and passed through a filter paper (0.22 μm, Whatman Inc., USA) [17, 18]. The 
filtrate was then subject to the UV-Vis spectrophotometric analysis 
against the blank (0.1 N HCl). With the help of the UV-Vis 
spectrophotometric standard calibration curve data, the percentage 
cumulative drug release estimated out at 291 nm (T60 UV-Visible 
Spectrophotometer, Labindia Analytical) [37, 38].  
In vitro drug release kinetic study 
The drug kinetics release mechanism achieved from hydrophilic 
matrices and the dissolution outcome of the respectively 
nanosuspension batch was processed with various kinetic equations, 
known as zero and first-order kinetics, Higuchi, Hixson-Crowell and 
Korsmeyer-Peppas model. To find out the kinetics release, 
information got from in vitro drug release readings plotted in 
different models of kinetic. 
Zero-order model 
From, the pharmaceutical dosage forms dissolution of the drug does 
not disaggregate and release the drug slowly (expecting that the 
particle surface area does not alter and no equilibrium situations 
acquired) and the graph plotted as % drug released Vs time in an ‘h’ 
can be expressed by 
 …. (1) 
Where, Q0 = initial concentration of drug at time t = 0, Qt = amount of 
drug dissolved at a time t, K0 = zero-order constant in 
concentration/time, t = time in an ‘h’ [39, 40]. 
First-order model 
The utilization of this model to drug dissolution characteristics was 
first intended by Gibaldi and Feldman (1967) and thereafter by 
Wagner (1969). This model is the necessity to decide the absorption 
and/or elimination of some drugs, regardless of whether it is hard to 
conceptualize this mechanism on a hypothetical premise. The 
diagram was a conspiracy as a log % cumulative drug last Vs time in 
an ‘h’ [39, 40]. 
 …. (2) 
Where Qt = percent of drug remaining at time t, Q0 = initial 
concentration of the drug, K = first-order constant, t = time in an ‘h’. 
Higuchi model 
It is a first mathematical model that defines drug release from a matrix 
system, recommended by Higuchi in 1961. This model depends on a 
various hypothesis that (1) Primary drug concentration in the matrix 
is lot elevated than drug solubility, (2) Drug diffusion happens just in 
one dimension (Edge impact should be shunned), (3) Drug particles 
are far lesser than the thickness of system, (4) expanding of matrix and 
dissolution are minor or negligible, (5) Drug diffusivity is steady, (6) 
Accurate sink condition constantly achieved in the release 
environment. The intrigue graph drowned % cumulative drug 
discharged Vs square root of time [39, 40]. 
…… (3) 
Where, Qt = amount of drug released at a time ‘t’ per unit area A, KH = 
Higuchi dissolution constant reflecting design variable system, t = 
time in an ‘h’. 
Hixon crowell model 
The particles that have a uniformed size, the equation derived by 
Hixson and Crowell describes the dissolution rate based on the 
weight of the particles cube root and the particle radius not assumed 
to be variable. It is calculated by the equation,  
 …. (4) 
In the pharmaceutical dosage form, the incipient amount of 
medicament is Q0 and the rest of the measure of medication in the 
pharmaceutical dosage form is Qt at a time ‘t’ and ‘KH’ is a Hixson-
Crowell proportionality consistent. From the acquit kinetics, 
information acquired from in vitro medicament release studies 
plotted as the cube root of % medicament remaining Vs time in an ‘h’ 
[39, 40]. 
Korsmeyer Peppa’s model …. (5) 
Where the quantity of drug release at the time ‘t’ is Mt, and the 
amount released at a time is M∞ where t =∞, thus Mt/M∞ is at a 
time ‘t’ fraction of drug released, the kinetic constant is known as ‘k’, 
and diffusion exponent is ‘n’ and for both solvent penetration and 
drug release mechanism characterized by the above equation. The 
correlation coefficient set up by executing the obtained data into 
various kinetic models and the greatest fit model affirmed by the 
estimation of the correlation coefficient close to 1 [19]. From the 
slope, the rate constants of respective models are calculated. The 
information was introduced for the most suitable model. If ‘n’ for 
(sphere) worth is 0.43 or a smaller amount, the mechanism of 
release pursues “fickian diffusion,” and upper estimations of 0.43-
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0.85 for the transport of mass pursue a non-fickian (anomalous 
transport) model. If the ‘n’ worth is 0.85 that means case II transport 
and the drug release pursues the Higuchi model. For the estimations 
of 'n' upper than 0.85, the mechanism of drug release is viewed as 
super case II transport [41, 42]. 
RESULTS  
 max and calibration curve 
Calibration curves of telmisartan in a buffer of 0.1 N HCL solutions 
built at  max recorded 291 nm with a (T60 UV-Visible 
Spectrophotometer, Labindia Analytical). Beer’s law followed to 
construct the calibration curve was in the concentration range of 5-30 μg/ml. The standard graph of telmisartan demonstrated great 
linearity with an R2 of 0.998, which indicates that it complies “Beer-
Lambert’s” law (fig. 1). The examination was done in triplicate [19, 
21, 23]. 
Experimental data analysis 
The 3 factors, 3 levels of the factorial design implemented for 
improvement. The SLS, poloxamer 188 amount and Tween 80 varied 
as stated in the strategy in table 3. Throughout the experiments 
entire the other processing variables, urea and water maintained 
fixed. Trial preliminaries were conducted at all 12 potential 
combinations [5, 17]. 
 
 
Fig. 1: Calibration curve of drug telmisartan mean of triplicate 
data specified (n= 3±SD) 
  
 
Fig. 2: FTIR spectrum of telmisartan (A) optimized formulation (B) scanned from 4000 cm-1 to 400 cm-1 
 
DISCUSSION 
Drug polymer interaction study 
The FTIR spectra of telmisartan nanosuspensions are shown in (fig. 2). 
Drug spectrum showed prominent peaks at 1691.43 cm, 2869.24 cm, 
1603.43 cm, 1381.08 cm, and 1757.40 cm correspondings to C=N-CH3 
imine stretching, C-H alkane, C=C aromatic stretching, C-N 3° amine 
stretching, and C-N stretching, respectively. Telmisartan 
nanosuspension shows similar peaks 1686.85 cm, 2850.48 cm, 
1577.40 cm, 1316.40 cm that corresponding to the C=N-CH3 Imine, C-
H Alkane, C=C Aromatic, C-N 3° amine of the FTIR spectra of pure drug, 
which shows no interaction amongst drug and polymer [28, 30, 36]. 
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Table 3: Formulation characteristics of 33 factorial design 
Formulation code Coded factors and their levels Coded factors and their actual values 
X1 X2 X3 X1 X2 X3 
F1 -1 - - 3 - - 
F2 0 - - 5 - - 
F3 1 - - 10 - - 
F4 - - -1 - - 0.1 
F5 - - 0 - - 0.2 
F6 - - 1 - - 0.3 
F7 - -1 - - 3 - 
F8 - 0 - - 4 - 
F9 - 1 - - 5 - 
F10 - 1 -1 - 5 0.1 
F11 - 1 0 - 5 0.2 
F12 - 1 1 - 5 0.3 
Note: (-) the particular excipient not utilized in the formulation 
 
Zeta potential measurement 
The average particle size of the drug in the optimized 
nanosuspension formulation (F12) was found to be approximately 
750 nm. The surface potency properties and along with the extended 
physical stability of the nanosuspensions, were carried out by zeta 
potential (fig. 3). The zeta potential of the formulation was found to 
be-24.33 mV, so it is sufficient for maintaining stable 
nanosuspension formulation in the presence of poloxamer 188 and 







Fig. 3: Size distribution and zeta potential of optimized nanosuspension (A) and (B) 
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Fig. 4: DSC graph of the pure drug (A) and optimized formulation (B) scanning rate of 10 °C min-1 and the analysis temperature range 25 °C 




Fig. 5: SEM photographs of nanosuspension at 50x magnification (A) and 500x magnification (B) 
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Differential scanning calorimetry 
DSC diagram demonstrates that the pure drug temperature (263.3 °C) 
reduced compared to the optimized nanosuspension formulation 
(F12) temperature (180 °C) is due to the drug charges from a 
crystalline state to an amorphous state. Generally, amorphous 
substances having a lower melting temperature than the crystalline 
substances in the manufacture of nanosuspension by precipitation 
technique. So crystalline substances having diminished solubility than 
the amorphous substances. The melting point of telmisartan found to 
be 261-263 °C, which complied with British Pharmacopoeia standards, 
thus indicating the purity of the obtained drug sample (fig. 4) [30-32]. 
Scanning electron microscopy 
Surface morphology and shape of optimized formulation 
nanoparticles imagined utilizing SEM (Model JSM 84 0A, JEOI, 
Japan). The drug-entrapped nanoparticles were looking like a 
smooth surface (fig. 5). The drug-loaded nanoparticles were 
observed to be, black color with a smooth surface and almost 
spherical. All nanoparticles' shapes and sizes are having almost 
uniform. In an SEM study, the nanoparticles' surface morphology 
and patterns visualized [20, 31, 38]. 
Dissolution study 
The telmisartan nanosuspension contains all the 12 formulations 
subjected to dissolution studies (fig. 6). In USP apparatus Type II, the 
dissolution test carried out by taking a 900 ml volume of dissolution 
media containing 0.1 N HCl solutions with a rotation speed of peddle 
at 50 rpm. The formulation F1 drug release rate was slower than the 
F2 and F2 drug release rate, also slower than F3, as a consequence of 
the increased concentration of SLS. The drug release rates between 
F4, F5, and F6 has observed that F6 (85% within 5 min) release rate 
was faster than the F5 (56% within 5 min) and F4 (44% within 5 
min) was due to increasing the concentration of Tween 80 in the 
increased order from F4 to F6. By adding poloxamer 188 
concentrations, in increased order i.e. 3 mg, 4 mg, and 5 mg from F7 
to F9, it noticed that the drug release rate is in ascending order from 
F7 (73% within 5 min), F8 (80% within 5 min) to F9 (89% within 5 
min). By monitoring the drug release rate data from F10 to F12 it 
concluded that the release rate of F12 was higher (95% within 5 
min) than the F11 (90% within 5 min) and F11 release rate is higher 
than F10 (89% within 5 min) due to the employment of two 
stabilizers in which ace is in a fixed amount i.e. 5 mg and another are 
in increasing order (0.1%, 0.2%, 0.3%) (table 1, fig. 6). The release 
rate between three polymers observed that poloxamer 188 having 
more release rate than the other two polymers (SLS and Tween 80). 
F12 is the optimized formulation because the drug releases for the 
F12 formulation is 95.45% in 5 min. This formulation contains 
stabilizers, particularly poloxamer 188 and Tween 80 [37, 38, 43]. 
In vitro drug release kinetic study 
To decide the release model which best portrays the model of drug 
release, the in vitro release information is substituted in different 
models, for example, zero and first order, Higuchi, Hixon Crowell, 
and Korsmeyer Peppas kinetics models. From the release kinetics 
information (table 4) it affirmed that the formulations F3 and F9 
obeyed the Higuchi kinetic model, which confirms that quick release 
of hydrophobic drug and F4, F5, and F7 obeyed Hixon-Crowell 
release. F8 follows zero-order release and F1, F2 and F6 follow the 
first-order release mechanism. The data indicate that the 
nanosuspension formulations F2 to F5 the drug release followed by 
the Fickian transport mechanism (n<0.43), whereas formulation F1, 
released the drug followed by non-Fickian (anomalous) transport 
mechanism (0.43<n<0.85) [42, 44]. 
 
 
Fig. 6: In vitro drug release profile of telmisartan nanosuspension mean of triplicate data specified (n= 3±SD) 
 
Table 4: In vitro drug release kinetic studies 
Formulations Zero-order First-order Higuchi Hixon crowell Release exponent 
(n) R2 
F1 0.847 0.942 0.938 0.915 0.786 
F2 0.760 0.987 0.986 0.982 0.333 
F3 0.956 0.942 0.994 0.986 0.376 
F4 0.805 0.898 0.900 0.921 0.398 
F5 0.997 0.979 0.979 0.998 0.266 
F6 0.924 0.999 0.968 0.998 - 
F7 0.940 0.974 0.984 0.995 - 
F8 0.999 0.970 0.987 0.916 - 
F9 0.989 0.923 0.999 0.975 - 
F10 1 1 1 1 - 
F11 1 1 1 1 - 
F12 1 1 1 1 - 
Note: (-) the particular result doesn't originate in the formulation, (R2 = regression coefficient, n = release exponent) 
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CONCLUSION 
A nanoprecipitation method produced to prepare nanosuspension of 
telmisartan using urea as a carrier and different concentrations of 
poloxamer 188, Tween 80, and SLS as a wetting agent. In the 
nanoprecipitation method, the particle size of telmisartan can be 
accomplished in the nanometer in size, by modifying operation 
parameters, like stabilizer concentration (% w/v). The best 
nanosuspension of telmisartan can be obtained by urea, poloxamer 
188, and Tween 80 using nanoprecipitation methods. A dissolution 
study in 0.1 N HCl solution shows that nanosuspension formulations 
F10, F11, and F12 drug releases within 10 min. Nanosuspensions 
represent a promising option to current drug delivery systems 
aiming to improve the biopharmaceutical performance of 
antihypertensive drug telmisartan with poor water solubility. 
Nanoprecipitation could thus be able to be a straightforward and 
effective way to deal with produce submicron particles of meanly 
weaken water-soluble drugs for upgrading solubility and 
bioavailability. 
STATEMENT OF HUMAN AND ANIMAL RIGHTS 
This clause does not contain any studies with human or animal 
subjects performed by any of the writers. 
ACKNOWLEDGEMENT 
The authors are thankful for Matrix Laboratory Limited, Hyderabad, 
India for supplying a gift sample of telmisartan. 
FUNDING 
Financial backing and sponsorship were nil. 
AUTHORS CONTRIBUTIONS 
From all 6 authors Sireeshaparticipated in the experimental work 
and Prasanta Kumar Mohapatrasupervised the entire project and 
writing of the manuscript. Bibhuti Prasad Rath, Harish Chandra 
Verma, Vaibhav Rathore, and Satyajit Sahoo have discussed the 
results and helped to write the manuscript. Prasanta Kumar 
Mohapatra acted as the corresponding author. 
CONFLICT OF INTERESTS 
The authors have declared no conflict of interest. 
REFERENCES 
1. Seedher N, Bhatia S. Solubility enhancement of Cox-2 inhibitors 
using various solvent systems. AAPS PharmSciTech 2003;4:36-
44. 
2. Wilkinson JM. Nanotechnology applications in medicine. Med 
Device Technol 2003;14:29-31. 
3. Sharma P, Denny WA, Garg S. Effect of wet milling process on 
the solid-state of Indomethacin and simvastatin. Int J Pharma 
2009;380:40-8.  
4. Roco MC. Nanotechnology: convergence with modern biology 
and medicine. Curr Opin Biotechnol 2003;14:337-46. 
5. Singh B, Chakkal KS, Ahuja N. Formulation and optimization of 
controlled release mucoadhesive tablets of atenolol using 
response surface methodology. AAPS PharmSciTech 
2006;7:19-28. 
6. Verma S, Kumar S, Gokhale R, Burgess DJ. Physical stability of 
nanosuspensions: investigation of the role of stabilizers on 
ostwald ripening. Int J Pharm 2011;406:145-52. 
7. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental 
and computational approaches to estimate solubility and 
permeability in drug discovery and development settings. Adv 
Drug Delivery Rev 2001;46:3-26. 
8. Patel VR, Agrawal YK. Nanosuspension: an approach to 
enhance the solubility of drugs. J Adv Pharm Tech Res 
2011;2:81-7. 
9. Bilati U, Allemann E, Doelker E. Nanoprecipitation versus 
emulsion-based techniques for the encapsulation of proteins 
into biodegradable nanoparticles and process-related stability 
issues. AAPS PharmSciTech 2005;6:594-604. 
10. Hassan MA, Suleiman MS,  Najib NM. Improvement of the in 
vitro dissolution characteristics of famotidine by inclusion in β-
cyclodextrin. Int J Pharm 1990;58:19-24. 
11. Urbanetz NA. Stabilization of solid dispersions of nimodipine 
and polyethylene glycol 2000. Eur J Pharm Sci 2006;28:67-76.  
12. Tripathi KD. Essentials of medical pharmacology. 6th ed. New 
Delhi, India: Jaypee Brothers, Medical Publishers Pvt Limited; 
2008. 
13. Jacobs C, Kayser MO, Muller MRH. Nanosuspensions as a new 
approach for the formulation for the poorly soluble drug 
tarazepide. Int J Pharm 2000;196:161-4. 
14. Li L, Kakran M,  Sahoo NG,  Judeh Z, Wang Y,  Chong K, et al. 
Fabrication of drug nanoparticles by evaporative precipitation 
of nanosuspension. Int J Pharm 2010;383:285-92. 
15. Zhong J, Shen ZG, Yang Y, Chen JF. Preparation and characterization 
of uniform nanosized cephradine by the combination of reactive 
precipitation and liquid antisolvent precipitation under high 
gravity environment. Int J Pharm 2005;301:286-93. 
16. Zhang JY, Shen ZG, Zhong J, Hu TT, Chen JF, Ma ZQ, et al. 
Preparation of amorphous cefuroxime axetil nanoparticles by 
controlled nanoprecipitation method without surfactants. Int J 
Pharm 2006;323:153-60. 
17. Pandya VM, Patel JK, Patel DJ. Formulation, optimization and 
characterization of simvastatin nanosuspension prepared by 
nanoprecipitation technique. Der Pharm Lett 2011;3:129-40. 
18. Jain V, Kare P, Jain D, Singh R. Development and 
characterization of mucoadhesive nanosuspension of 
ciprofloxacin. Acta Poloniae Pharm Drug Res 2011;68:273-8. 
19. Pandey N, DrSah AN, Mahara K. Formulation and evaluation of 
floating microspheres of nateglinide. Int J Pharm Sci Res 
2016;7:453-64. 
20. Jassem NA, Rajab NA. Formulation and in vitro evaluation of 
azilsartan medoxomil nanosuspension. Int J Pharm Pharm Sci 
2017;9:110-9. 
21. Sumathi R, Tamizharasi S, Sivakumar T. Formulation and 
evaluation of polymeric nanosuspension of naringenin. Int J 
Appl Pharm 2017;9:60-70. 
22. Anjane M, Agrawal S, Khan A. Formulation and evaluation of 
nanosuspension of Valsartan. Int J Curr Pharm Res 2018;10:68-74. 
23. Singhvi G, Canchi A, Khosa A, Banerjee S, Dubey SK. Design and 
characterization of polymeric nanoparticles of pioglitazone 
hydrochloride and study the effect of formulation variables 
using QbD approach. Curr Nanomater 2017;2:162-8.  
24. Zhao X, Zu Y, Li Q, Wang M, Zu B, Zhang X, et al. Preparation and 
characterization of camptothecin powder micronized by a 
supercritical antisolvent (SAS) process. J Supercritical Fluids 
2010;51:412-9. 
25. Li L, Kakran M,  Sahoo NG,  Judeh Z, Wang Y,  Chong K, et al. 
Fabrication of drug nanoparticles by evaporative precipitation 
of nanosuspension. Int J Pharm 2010;383:285-92. 
26. Sreeramulu J, Reddy MS, Jayaraju A, Rafiyuddin M. Formulation 
and evaluation of sildenafil citrate nanosuspension. Int J Pharm 
2016;6:137-42. 
27. Revathi S, Dhanaraju MD. Optimization and characterization 
ezogabine-loaded nanosuspension for enhancement of 
bioavailability by “bottom-up” technology using 32 factorial 
design. J Drug Delivery Ther 2019;9:227-37. 
28. Mothilal M, Krishna MC, Teja SPS, Manimaran V, Damodharan 
N. Formulation and evaluation of naproxen-eudragit® RS 100 
nanosuspension using 32 factorial design. Int J Pharm Pharm 
Sci 2014;6:449-55. 
29. Barar J, Salatin S, Jalali MB, Adibkia K, Milani MA, Jelvehgari M, 
et al. Formulation and evaluation of eudragit RL-100 
nanoparticles loaded in-situ forming gel for intranasal delivery 
of rivastigmine. Adv Pharm Bull 2020;10:20-9. 
30. Yang J, Liu Q, Mai Y, Gu X, Zhao Y, Di X, et al. A wet-milling 
method for the preparation of cilnidipine nanosuspension with 
enhanced dissolution and oral bioavailability. J Drug Delivery 
Sci Tech 2020;55:1773-2247. 
31. Dhanalakshmi M, Nagajyothi N, Thenmozhi S, Natarajan R, 
Rajendran NN. Formulation and evaluation of pitavastatin 
nanosuspension. Int J Pharm Life Sci 2014;5:3318-24. 
Mohapatra et al. 
Int J App Pharm, Vol 12, Issue 5, 2020, 286-294 
294 
32. Deshkar SS, Sonkamble KG, Mahore JG. Formulation and 
optimization of nanosuspension for improving solubility and 
dissolution of gemfibrozil. Asian J Pharm Clin Res 2019;12:157-63. 
33. Mahajan A, Kaur S. Design, characterization and pharmacokinetic 
studies of solid lipid nanoparticles of antihypertensive drug 
telmisartan. Int J Pharm Sci Res 2017;8:3402-12. 
34. El-Sherbiny IM, Elbaz NM, Khalil IA, Abd-Rabou AA. Chitosan-based 
nano-in-microparticle carriers for enhanced oral delivery and 
anticancer activity of propolis. Int J Bio Macromol 2016;92:254-69.  
35. Dahiya M, Pandey P. A brief review on inorganic nanoparticles. 
J Crit Rev 2016;3:18-26. 
36. Ethiraj T, Sujitha R, Ganesan V. Formulation and in vitro evaluation 
of nanosuspension of glimepiride. Int J Pharm 2013;3:875-82. 
37. Murthy KVR, Raju V. Development and validation of new 
discriminative dissolution method for carvedilol tablets. Indian 
J Pharm Sci 2011;73:527-36. 
38. Bajaj A, Rao MRP, Pardeshi A, Sali D. Nanocrystallization by 
evaporative antisolvent technique for solubility and bioavailability 
enhancement of telmisartan. AAPS PharmSciTech 2012;13: 
1331-40. 
39. Costa P, Lobo JMS. Modeling and comparison of dissolution 
profiles. Eur J Pharm Sci 2001;13:123-33. 
40. Ramteke KH, Dighe PA, Kharat AR, Patil SV. Mathematical 
models of drug dissolution: a review. Sch Acad J Pharm 
2014;3:388-96. 
41. Peppas NA, Sahlin JJ. A simple equation for the description of 
solute release. coupling of diffusion and relaxation. Int J Pharm 
1989;57:169-72. 
42. Siepmann J, Peppas NA. Modeling of drug release from delivery 
systems based on hydroxypropyl methylcellulose (HPMC). Adv 
Drug Delivery Rev 2012;64:163-74. 
43. Abbas HK, Abood AN, Fatimah M, Wais H. Preparation and 
evaluation of ketoprofen nanosuspension using solvent 
evaporation technique. Iraqi J Pharm Sci 2017;26:41-55. 
44. Siepmann J, Siepmann F. Mathematical modeling of drug 
delivery. Int J Pharm 2008;364:328-43. 
 
